18413839 |
EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation
Trowe, T,
Fong, R,
Woolfrey, JR,
Lamb, P,
Yang, JP,
Gerritsen, ME,
Cutler, RE,
Miller, N,
Vysotskaia, V,
Funke, R,
Kim, YD,
Gendreau, SB,
Heuer, TS,
Boukouvala, S,
Matthews, DJ,
Calkins, K
|
Clin. Cancer Res. |
2008 |
17311002 |
The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272
Meyerson, M,
Thomas, RK,
Wong, KK,
Weir, BA,
Haringsma, HJ,
Lee, JC,
Liniker, E,
Shimamura, T,
Shapiro, GI,
Glatt, KA,
LaFramboise, T,
Minami, Y,
Lowell, AM,
Borgman, CL,
Feng, W,
Wolf, J,
Shah, K
|
Oncogene |
2007 |
26375550 |
Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor
Xi, R,
Hu, Z,
Liu, X,
Xie, Q,
Chen, L,
Zhang, A,
Liu, D,
Hu, Y
|
Oncotarget |
2015 |
29967253 |
High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2
Kojima, S,
Ueno, T,
Iwase, H,
Nagano, M,
Kohsaka, S,
Mano, H,
Saka, K,
Kawazu, M
|
Clin. Cancer Res. |
2018 |
22046346 |
Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib
Duyster, J,
Kancha, RK,
Engh, RA,
Peschel, C,
Bartosch, N,
von Bubnoff, N
|
PLoS ONE |
2011 |
30854046 |
Anti-tumor effect of neratinib against lung cancer cells harboring HER2 oncogene alterations
Suzawa, K,
Kurihara, E,
Sato, H,
Yoshioka, T,
Takahashi, Y,
Tomida, S,
Shien, K,
Ogoshi, Y,
Torigoe, H,
Namba, K,
Soh, J,
Toyooka, S,
Sakaguchi, M,
Yamamoto, H
|
Oncol Lett |
2019 |
26545934 |
Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations
Suzawa, K,
Hashida, S,
Watanabe, M,
Ohtsuka, T,
Tomida, S,
Maki, Y,
Asano, H,
Miyoshi, S,
Morita, M,
Tsukuda, K,
Soh, J,
Toyooka, S,
Sakaguchi, M,
Yamamoto, H
|
Cancer Sci. |
2016 |
25853726 |
Phosphorylation of mutationally introduced tyrosine in the activation loop of HER2 confers gain-of-function activity
Hao, R,
Wang, P,
Hu, Z,
Li, L,
Zhang, A,
Chen, S,
Gao, Y,
Luan, Z,
Zhang, H,
Huang, N,
Wan, X,
Wei, M,
Xie, Q,
Chen, L,
Li, L
|
PLoS ONE |
2015 |
28274957 |
An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer
Hyman, DM,
Solit, DB,
Nagy, R,
Sheehan, JH,
Sliwoski, GR,
Berger, MF,
He, J,
Lalani, AS,
Brewer, MR,
Miller, V,
Cross, D,
Cutler, RE,
Hanker, AB,
Lanman, R,
Arteaga, CL,
Koch, JP,
Lovly, CM,
Meiler, J
|
Cancer Discov |
2017 |
23220880 |
Activating HER2 mutations in HER2 gene amplification negative breast cancer
Bose, R,
Shen, W,
Aronson, AB,
Goel, N,
Koboldt, DC,
Li, S,
Searleman, AC,
Ma, CX,
Ellis, MJ,
Shen, D,
Ding, L,
Monsey, J,
Mardis, ER,
Kavuri, SM
|
Cancer Discov |
2013 |